Jabs Douglas A, Van Natta Mark L, Holbrook Janet T, Kempen John H, Meinert Curtis L, Davis Matthew D
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ophthalmology. 2007 Apr;114(4):780-6. doi: 10.1016/j.ophtha.2006.11.008. Epub 2007 Jan 25.
To report the prevalence of ocular complications of AIDS in the era of highly active antiretroviral therapy (HAART).
Cohort study.
Patients with AIDS, 13 years or older.
History, eye examination, and laboratory testing at enrollment.
Frequency of ocular complications at enrollment.
As of March 31, 2003, 1632 participants with AIDS were enrolled. The cohort had a history of severe immune deficiency, as evidenced by a median nadir CD4+ T-cell count of 30 cells per microliter. At enrollment, the median CD4+ T-cell count was 164 cells per microliter. CD4+ T-cell counts were <50 in 24.1% but > or =100 in 63.6% and > or =200 in 43.0%. Cytomegalovirus (CMV) retinitis was present in 22.1%, whereas other ocular opportunistic infections each were present in < or =0.6%. The incidence of CMV retinitis estimated from retrospective data was 5.60/100 person-years. Of the 360 patients with CMV retinitis, 22.5% were newly diagnosed at enrollment, and the remainder had more long-standing CMV retinitis (median, 2.8 years).
Although there is the possibility of oversampling patients with AIDS and ocular complications (as compared with a random sample), which would lead to increased estimates of prevalent and incident ocular morbidities, these data still suggest a substantial decline in the incidence of CMV retinitis from the pre-HAART era. Nevertheless, new cases of CMV retinitis continue to occur, and there is a population of patients with long-standing retinitis who will require management.
报告高效抗逆转录病毒治疗(HAART)时代艾滋病眼部并发症的患病率。
队列研究。
13岁及以上的艾滋病患者。
入组时进行病史采集、眼部检查和实验室检测。
入组时眼部并发症的发生率。
截至2003年3月31日,共入组1632例艾滋病患者。该队列有严重免疫缺陷病史,中位最低点CD4 + T细胞计数为每微升30个细胞。入组时,中位CD4 + T细胞计数为每微升164个细胞。24.1%的患者CD4 + T细胞计数<50,但63.6%的患者>或 = 100,43.0%的患者>或 = 200。巨细胞病毒(CMV)视网膜炎的患病率为22.1%,而其他眼部机会性感染的患病率均≤0.6%。根据回顾性数据估计的CMV视网膜炎发病率为5.60/100人年。在360例CMV视网膜炎患者中,22.5%在入组时为新诊断病例,其余患者的CMV视网膜炎病程更长(中位病程2.8年)。
尽管可能存在对艾滋病和眼部并发症患者的过度抽样(与随机样本相比),这会导致对眼部疾病患病率和发病率的估计增加,但这些数据仍表明与HAART治疗前时代相比,CMV视网膜炎的发病率大幅下降。然而,CMV视网膜炎的新病例仍在继续出现,并且有一群患有长期视网膜炎的患者需要管理。